EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Safety and Effectiveness of Biktarvy ® (bictegravir/emtricitabine/tenofovir alafenamide) in Patients with HIV-1 Infection: Interim Report of a Post-Marketing Surveillance Study in Korea

Shin-Woo Kim iD, Jami Peters iD, Markus G Lang iD, Jeong-A Lee iD, Jinhye Cha iD, Yeon-Sook Kim iD

Infection & Chemotherapy · 2026 · 58 (1) · 122

DOI: 10.3947/ic.2025.0140 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Infection & Chemotherapy, 2026. Verfasst von Shin-Woo Kim und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Korea. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Gilead Sciences Korea Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

BictegravirEmtricitabineKoreaPostmarketing product surveillanceTenofovir alafenamide

Autor:innen und Institutionen

  • Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Korea.
  • Gilead Sciences, Inc., Foster City, CA, USA.
  • Gilead Sciences Korea, Seoul, Korea.
  • Division of Infectious Diseases, Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, Korea. alice@cnuh.co.kr.

ORCID-Profile: Shin-Woo Kim, Jami Peters, Markus G Lang, Jeong-A Lee, Jinhye Cha, Yeon-Sook Kim

Förderung

  • Gilead Sciences Korea Ltd.

Zitieren

APA

Kim, S. W., Peters, J., Lang, M. G., Lee, J. A., Cha, J., & Kim, Y. S. (2026). Safety and Effectiveness of Biktarvy ® (bictegravir/emtricitabine/tenofovir alafenamide) in Patients with HIV-1 Infection: Interim Report of a Post-Marketing Surveillance Study in Korea. Infection & Chemotherapy, 58(1), 122. https://doi.org/10.3947/ic.2025.0140

Vancouver

Kim SW, Peters J, Lang MG, Lee JA, Cha J, Kim YS. Safety and Effectiveness of Biktarvy ® (bictegravir/emtricitabine/tenofovir alafenamide) in Patients with HIV-1 Infection: Interim Report of a Post-Marketing Surveillance Study in Korea. Infection & Chemotherapy. 2026;58(1):122. doi:10.3947/ic.2025.0140

BibTeX
@article{Kim2026,
  author = {Kim, Shin-Woo and Peters, Jami and Lang, Markus G and Lee, Jeong-A and Cha, Jinhye and Kim, Yeon-Sook},
  title = {Safety and Effectiveness of Biktarvy ® (bictegravir/emtricitabine/tenofovir alafenamide) in Patients with HIV-1 Infection: Interim Report of a Post-Marketing Surveillance Study in Korea},
  journal = {Infection & Chemotherapy},
  year = {2026},
  volume = {58},
  number = {1},
  pages = {122},
  doi = {10.3947/ic.2025.0140}
}
Kostenlos starten →